Mepolizumab does not alter blood basophil count in severe asthma
2019
Introduction: Mepolizumab (anti-human IL5) reduces blood eosinophils, however, it is less well known that blood basophils, also IL-5 receptor positive, are also decreased in routine clinical tests. Aims and Objectives: Our objective was to determine whether mepolizumab treatment reduces blood basophil levels in severe asthma as an additional potential efficacy mechanism. Methods: Asthma patients receiving mepolizumab in a single-centre, difficult asthma clinic were recruited for blood collection prior to and ~16 weeks after treatment (n=24). Samples from healthy subjects, collected at parallel time-points but without an intervention, acted as controls. The concentration of basophils, eosinophils (positive control) and other Type-2 lymphocytes were measured (cells/100μl blood) by flow cytometry (Attune NxT) and compared to routine clinical measurements using an Advia 2120. Results: Following 16-weeks of treatment, eosinophils were reduced [Δ -6,442±6,852, p Conclusion: These data suggest that the basophil concentration reported clinically should be interpreted with caution and that basophil numbers are unlikely to be affected in response to mepolizumab in severe asthma.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI